Evolution of serum carcinoembryonic antigen in head and neck carcinoma patients

Background: Malignancies of the head and neck region are top five leading cancer sites in India. Carcinoembryonic antigen (CEA), which belongs to a family of related cell surface glycoprotein’s, is the most often utilized tumor marker in the clinical practice. It is a tumor marker for colorectal, gastrointestinal, lung, Head & Neck, and breast cancer. Aims and Objectives: The present study was planned to evaluate the levels of CEA in patients with head and neck carcinoma. Materials and Methods: In the present case control study, serum CEA was determined in 50 Head and Neck cancer patients and 50 age matched healthy individuals were taken as control. Diagnosed cases of Head and Neck cancer age above 18 years were included and patients on chemotherapy and radiotherapy and patients after surgery were excluded from the study. Results: On comparing serum CEA levels with control group, a significant increase in serum CEA levels was noted in cases (2.70±1.71) ng/ml when compared with control group (1.90±0.57) ng/ml. Conclusion: Evaluation of CEA at an early stage of cancer can be helpful in predicting its prognosis and hence guide the treatment protocol

Breast cancer · Cancer · Carcinoembryonic antigen · Carcinoma · Chemotherapy · Colorectal cancer · Head and neck · Head and neck cancer · Lung cancer · Radiation therapy · Stage (stratigraphy · Tumor marker · Glycosylation and Glycoproteins Research · Lung Cancer Research Studies · Medicine · Radiopharmaceutical Chemistry and Applications · Internal Medicine · Oncology · Surgery

• Estimates of worldwide burden of cancer in 2008

  Open Access•J Ferlay, Hai‐Rim Shin et al.•International Journal of Cancer•2010

  Incluir item